Connor Clark and Lunn Investment Management Ltd. bought a new stake in shares of Rigel Pharmaceutica

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutra

HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) wi

VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new t

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patient

Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year d

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and n

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $275.000 million-$290.000 milli

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the an

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million an

SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL

SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nas

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Di

Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clini

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is enteri

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol

Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the poten

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the

 Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. (&#34

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hema

U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd

Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.12 per share which missed the